The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
This study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL CL) received R-CHOP program (as 1 st and2 nd line therapy), including cases with complications. We observed 77 DBLCL patients (50 primary and 27 received other chemotherapy programs, in relapse, progress...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/86 |
| _version_ | 1797855570657542144 |
|---|---|
| author | T. D. Lutskaya A. K. Golenkov T. A. Mitina I. V. Buravtsova G. A. Dudina L. L. Vysotskaya E. V. Trifonova E. V. Kataeva O. V. Moskalets V. V. Yazdovskiy |
| author_facet | T. D. Lutskaya A. K. Golenkov T. A. Mitina I. V. Buravtsova G. A. Dudina L. L. Vysotskaya E. V. Trifonova E. V. Kataeva O. V. Moskalets V. V. Yazdovskiy |
| author_sort | T. D. Lutskaya |
| collection | DOAJ |
| description | This study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL CL) received R-CHOP program (as 1 st and2 nd line therapy), including cases with complications. We observed 77 DBLCL patients (50 primary and 27 received other chemotherapy programs, in relapse, progression or treatment resistance phase). The median age is 54.1 years (21–79 years). 33 patients (43 %) had a high risk for unfavorable disease course according to IPI. Complications associated with development of severe compression syndromes, which required the appropriate surgical intervention, w as diagnosed in 45 (58.4 %) patients. From 50 primary patients received R-C HOP as the f irst line therapy objective treatment response was registered in 47 (94.0 %). Complete response was registered in 43 (86.0 %). The proportion of patients in whom response was maintained for 6 months w as 72.0 % in group with maintenance therapy and 28.0 % in group without it. These results were achieved when induction period density was 0.9. The last parameter is the ratio of the courses number to their time in mon ths. The density of standard induction R-C HOP-21 is 1.4. From 27 relapse or refractory patients received R-C HOP as the second line therapy objectivetreatment response was registered in 85.1 % of patients. Induction period density w as 1.03. The proportion of patients in whom response was maintained for 6 months was 74.0 %. Three classes serum Ig concentrations analysis before and after induction period in 16 pati ents showed normal values. With the median (Me) follow-up time in all patients over 24 months 3-years survival w as 93 % and Me w as not achieved. 3-years survival was 100 % in primary patients and 80 % in patients with previously treatment, and Me is also not achieved. |
| first_indexed | 2024-04-09T20:25:59Z |
| format | Article |
| id | doaj.art-e20d53490faa485f97b18a49fc3a21f9 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:25:59Z |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-e20d53490faa485f97b18a49fc3a21f92023-03-30T20:15:10ZrusABV-pressОнкогематология1818-83462413-40232014-07-0163182310.17650/1818-8346-2011-6-3-18-23101The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphomaT. D. Lutskaya0A. K. Golenkov1T. A. Mitina2I. V. Buravtsova3G. A. Dudina4L. L. Vysotskaya5E. V. Trifonova6E. V. Kataeva7O. V. Moskalets8V. V. Yazdovskiy9M.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteM.F. Vladimirsky Moscow Regional Research Clinical InstituteThis study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL CL) received R-CHOP program (as 1 st and2 nd line therapy), including cases with complications. We observed 77 DBLCL patients (50 primary and 27 received other chemotherapy programs, in relapse, progression or treatment resistance phase). The median age is 54.1 years (21–79 years). 33 patients (43 %) had a high risk for unfavorable disease course according to IPI. Complications associated with development of severe compression syndromes, which required the appropriate surgical intervention, w as diagnosed in 45 (58.4 %) patients. From 50 primary patients received R-C HOP as the f irst line therapy objective treatment response was registered in 47 (94.0 %). Complete response was registered in 43 (86.0 %). The proportion of patients in whom response was maintained for 6 months w as 72.0 % in group with maintenance therapy and 28.0 % in group without it. These results were achieved when induction period density was 0.9. The last parameter is the ratio of the courses number to their time in mon ths. The density of standard induction R-C HOP-21 is 1.4. From 27 relapse or refractory patients received R-C HOP as the second line therapy objectivetreatment response was registered in 85.1 % of patients. Induction period density w as 1.03. The proportion of patients in whom response was maintained for 6 months was 74.0 %. Three classes serum Ig concentrations analysis before and after induction period in 16 pati ents showed normal values. With the median (Me) follow-up time in all patients over 24 months 3-years survival w as 93 % and Me w as not achieved. 3-years survival was 100 % in primary patients and 80 % in patients with previously treatment, and Me is also not achieved.https://oncohematology.abvpress.ru/ongm/article/view/86diffuse b-large cells lymphomarituximab |
| spellingShingle | T. D. Lutskaya A. K. Golenkov T. A. Mitina I. V. Buravtsova G. A. Dudina L. L. Vysotskaya E. V. Trifonova E. V. Kataeva O. V. Moskalets V. V. Yazdovskiy The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma Онкогематология diffuse b-large cells lymphoma rituximab |
| title | The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma |
| title_full | The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma |
| title_fullStr | The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma |
| title_full_unstemmed | The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma |
| title_short | The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma |
| title_sort | efficacy of therapy with rituximab r chop in patients with diffuse large cells lymphoma |
| topic | diffuse b-large cells lymphoma rituximab |
| url | https://oncohematology.abvpress.ru/ongm/article/view/86 |
| work_keys_str_mv | AT tdlutskaya theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT akgolenkov theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT tamitina theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT ivburavtsova theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT gadudina theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT llvysotskaya theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT evtrifonova theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT evkataeva theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT ovmoskalets theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT vvyazdovskiy theefficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT tdlutskaya efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT akgolenkov efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT tamitina efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT ivburavtsova efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT gadudina efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT llvysotskaya efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT evtrifonova efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT evkataeva efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT ovmoskalets efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma AT vvyazdovskiy efficacyoftherapywithrituximabrchopinpatientswithdiffuselargecellslymphoma |